Loading
A phase 2 trial of Carboplatin, Bevacizumab, Olaparib in ovarian cancer, run by AbbVie, now recruiting.
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies is a phase 2 interventional study registered as NCT07024784 by AbbVie, with 377 participants planned, started 2025-07-30 and due to reach its primary completion in 2028-01. Interventions recorded: IMGN151, Carboplatin, Bevacizumab, Olaparib. Conditions listed: Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin, Ovarian cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin, Ovarian cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Ovarian cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Carboplatin, Ovarian cancer.
Shares Olaparib, Ovarian cancer.
Shares Olaparib, Carboplatin, Ovarian cancer.
Shares Olaparib, Bevacizumab, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/